- Number of patients reached in 2024 jumps 8% to 66 million
- R&D investments rise to EUR 6.2 billion, 23.2% of group net sales
- Company prepares new product launches starting in 2025
Boehringer Ingelheim today announced a continued rise in the number of patients it reached, 66 million in 2024, up 8.0% from the previous year. Development of its current product pipeline is well on track, as the company prepares multiple new product launches, starting in 2025. Research & Development (R&D) investments rose to EUR 6.2 billion, or 23.2% of group net sales. Group net sales rose by 6.1%* to EUR 26.8 billion.
"As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal phase of high investments," said Hubertus von Baumbach, Chairman of the Board of Managing Directors. "It is important that we use every opportunity to bring these new treatments to patients as fast as possible - this is our number one priority."
Human Pharma: investing in existing products and new launches
Human Pharma sales rose by 7.0%* to EUR 21.9 billion, led by JARDIANCE® and OFEV®. Sales of JARDIANCE®, which is now also available for treatment of chronic kidney diseases, in addition to type 2 diabetes and heart failure, rose 14.6%* to EUR 8.4 billion. OFEV®, which is used to treat idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, grew 8.9%* to EUR 3.8 billion.
The Human Pharma pipeline includes over ten new Phase II and III trials over the next 12 to 18 months, which will potentially result in a range of significant launches in the next five years. Human Pharma R&D spending rose to EUR 5.7 billion, or 27.6% of the business unit's net sales.
"If we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R&D," said Frank Hübler, Member of the Board of Managing Directors with responsibility for Finance. "With the innovations currently in our pipeline we will further increase investments in R&D in the years to come."
After positive data from pivotal studies, the company is preparing multiple new product launches, starting this year with potential launches of zongertinib and nerandomilast.
Nerandomilast has the potential to advancecare for patients with Idiopathic Pulmonary Fibrosis (FIBRONEER-IPF) and Progressive Pulmonary Fibrosis (FIBRONEER-ILD). Full data from both phase III FIBRONEER-trials, which met their primary endpoint, will be presented in the coming months.
If approved, zongertinib would be the first orally administered, targeted therapy for previously treated HER2-mutated lung cancer patients. Zongertinib's development was accelerated due to positive Phase 1b Beamion LUNG-1 trial data, which showed a response rate of 71% (95% CI, 60-80), p<0.0001**, and disease control rate of 93%. It was generally well tolerated, with a low toxicity-related discontinuation rate (3%). Additional studies in HER2-altered solid tumors are ongoing.
Bothzongertinib and nerandomilast have been submitted to regulatory authorities globally and first launches in the US are anticipated in the second half of this year, pending approval.
Animal Health: rapid response against transboundary animal diseases
Animal Health sales rose 1.9%* to EUR 4.7 billion in 2024, mainly driven by Pet Parasiticides and Therapeutics, Poultry and Ruminant. The parasiticides NEXGARD® continued to strengthen its position as the top-selling brand in the industry, growing 14.0%* to EUR 1.4 billion.
Last year, Boehringer Ingelheim supported livestock producers and governments by quickly providing vaccines and technical assistance for outbreaks of transboundary animal diseases.??
Attachment
- Boehringer Laboratory (https://ml-eu.globenewswire.com/Resource/Download/4d5097bc-851c-4232-b6a8-eb006cec3cda)
